Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

Aggarwal Rahul; Thomas Scott; Pawlowska Nela; Bartelink Imke; Grabowsky Jennifer; Jahan Thierry; Cripps Amy; Harb Armand; Leng Jim; Reinert Anne; Mastroserio Ilaria; Thach-Giao Truong; Ryan Charles J.; Munster Pamela N.

首页> 外文期刊>Journal of Clinical Oncology >Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

【24h】

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

机译：抑制组蛋白脱乙酰化酶作为抗血管生成抑制剂抗性的手段：I相研究Abexinostat Plus Pazopanib在先进的实体肿瘤恶性肿瘤中

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第11期|共9页
作者
Aggarwal Rahul; Thomas Scott; Pawlowska Nela; Bartelink Imke; Grabowsky Jennifer; Jahan Thierry; Cripps Amy; Harb Armand; Leng Jim; Reinert Anne; Mastroserio Ilaria; Thach-Giao Truong; Ryan Charles J.; Munster Pamela N.;
展开▼
作者单位

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

Univ Calif San Francisco 1450 3rd St San Francisco CA 94143 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies [J] . Aggarwal Rahul, Thomas Scott, Pawlowska Nela, Journal of Clinical Oncology . 2017,第11期

机译：抑制组蛋白脱乙酰化酶作为抗血管生成抑制剂抗性的手段：I相研究Abexinostat Plus Pazopanib在先进的实体肿瘤恶性肿瘤中
2. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies [J] . Collier Katharine A., Valencia Hugo, Newton Herbert, Cancer chemotherapy and pharmacology. . 2021,第5期

机译：组蛋白脱乙酰化酶抑制剂Ar-42的1阶段试验在神经纤维瘤病2型相关肿瘤和晚期固体恶性肿瘤患者中
3. A phase i study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors [J] . VenugopalB., BairdR., KristeleitR.S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第15期

机译：晚期实体瘤患者喹诺酮（JNJ-26481585）（一种口服异羟肟酸组蛋白脱乙酰酶抑制剂）的I期研究，具有靶标调节和抗肿瘤活性的证据
4. Epigenetic Silencing of Caspase-8: A Novel Mechanism of Drug Resistance Which Can Be Overcome by Demethylating Agents, Histone Deacetylase Inhibitors, IFNy or Caspase-8 Gene Transfer [C] . S. Fulda, K.-M. Debatin European Haematology Association . 2002

机译：Caspase-8的表观遗传沉默：通过去甲基化试剂，组蛋白脱乙酰酶抑制剂，IFNY或Caspase-8基因转移可以克服一种新型耐药机理
5. Upregulation of Somatostatin Receptor 2 in Neuroendocrine Tumors Using Histone Deacetylase Inhibitors [D] . Guenter, Rachael. 2021

机译：用组蛋白脱乙酰酶抑制剂对神经内分泌肿瘤进行生长抑素受体2的上调
6. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies [O] . Rahul Aggarwal, Scott Thomas, Nela Pawlowska, -1

机译：抑制组蛋白脱乙酰基酶作为逆转对血管生成抑制剂的抗性：Abexinostat加Pazopanib在晚期实体瘤恶性肿瘤中的I期研究
7. A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors [O] . Balaji Venugopal, Richard Baird, Rebecca S. Kristeleit, 2013

机译：Quisinostat（JNJ-26481585），口服羟肟酸酯组蛋白脱乙酰酶抑制剂，具有靶调制和抗肿瘤活性的阶段研究，具有晚期实体瘤的患者

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

摘要

著录项

相似文献

相关主题

期刊订阅